Krista McCay is a writer specializing in video game guides and walkthroughs. She first entered the industry in 2022 while studying English at UC Santa Barbara and working part-time as an editor. It ...

Somiya Adrees is a writer at GameRant. Her gaming journey began at a young age with classics like Super Mario Bros., Sonic the Hedgehog, and Disney's Aladdin in Nasira's Revenge (all of which she ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Traditional approval was supported by BREAKWATER, a randomized, open-label phase 3 study in first-line BRAF V600E–mutant metastatic CRC comparing encorafenib/cetuximab plus chemotherapy against ...

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial. A targeted treatment that includes Braftovi ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Check out the reveal trailer for Mutation Overload. An action-roguelike where you play a mad scientist clearing out rooms with a variety of weaponry. Smashing, shooting and slashing your way through ...

Frequently affected by so-called oncogenic mutations, BRAF is implicated in several human cancers. In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide. The ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...